<DOC>
	<DOCNO>NCT01088477</DOCNO>
	<brief_summary>In 50 breast cancer patient , heavily pretreated anti-hormonal therapy , investigator evaluate use 16-alpha [ 18-fluoro ] -17beta-estradiol positron emission tomography ( FES-PET ) predictive biomarker response estrogen therapy .</brief_summary>
	<brief_title>Imaging ER Density Guide Improve Tailored Therapy Acquired Anti-hormonal Resistant Breast Cancer</brief_title>
	<detailed_description>The estrogen receptor ( ER ) express approximately 70 % breast carcinoma . In general , patient anti-hormonal therapy therapy first choice . Despite good response 50-60 % patient , unfortunately patient develop ( acquire ) resistance . Patients acquire anti-hormonal resistance subdivide three different group : ( 1 ) patient lose ER-expression ( ~25 % ) , ( 2 ) patient preserve ER-expression ( ~55 % ) ( 3 ) patient enhance ER-expression ( ~30 % ) . Several study suggest different treatment strategy three different ER-phenotypes antihormonal resistant breast cancer . In patient acquire anti-hormonal resistance , ~30 % patient still respond hormone-additive therapy estrogen . In vitro study show estrogen-induced apoptosis long-treated estrogen deprive cell ( simulate aromatase inhibitor resistance ) . It suggest estrogen-hypersensitivity accompanied increase ER-expression . Whole-body image ER-density possible positron emission tomography 16-alpha [ 18-fluoro ] -17beta-estradiol tracer ( FES-PET ) . FES-PET show predictive biomarker response first line anti-hormonal therapy . In study include 50 patient , heavily pretreated anti-hormonal therapy . All patient undergo FES-PET baseline start estrogen therapy . Investigators patient blind FES-PET result . Responders non-responders define use RECIST criterion clinical follow-up . After response determine , FES-PET result analyze . We hypothesize patient respond estrogen therapy identify basis high ER-expression determine FES-PET .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Patients diagnosis acquire antihormonal resistant advance breast cancer show progression two line antihormonal treatment ; 2 . Treatment estradiol start ; 3 . Age &gt; 18 year ; 4 . ECOG performance status 02 . 1 . Life Expectancy &lt; 3 month ; 2 . Uncontrolled CNS metastasis ; 3 . History thrombosis ; 4 . Uncontrolled hypercalcemia ; 5 . Treatment investigational drug within 30 day start study ; 6 . Serious uncontrolled concurrent illness , e.g . autoimmune disorder ; 7 . New York Hearth Association ( NYHA ) class III/IV congestive heart failure ; 8 . Dyspnea rest due cause ; 9 . Pregnant lactating woman . Documentation negative pregnancy test must available premenopausal woman intact reproductive organ woman less two year menopause ; 10 . Women childbearing potential unless ) surgically sterile b ) use adequate measure contraception . 11 . Diabetes Mellitus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Acquired anti-hormonal resistant breast cancer</keyword>
</DOC>